Immunotherapies for COVID-19: lessons learned from sepsis
Open Access
- 28 April 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 8 (10), 946-949
- https://doi.org/10.1016/s2213-2600(20)30217-4
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cytokine storm and sepsis disease pathogenesisSeminars in Immunopathology, 2017
- IL-6 in Inflammation, Immunity, and DiseaseCold Spring Harbor Perspectives in Biology, 2014
- Treatment of Progressive Multifocal Leukoencephalopathy With Interleukin 7JAMA Neurology, 2014
- Parallels between Cancer and Infectious DiseaseThe New England Journal of Medicine, 2014
- Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)Proceedings of the National Academy of Sciences of the United States of America, 2013
- Ipilimumab-Induced Hepatitis C Viral SuppressionJournal of Clinical Oncology, 2013
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus InfectionPLOS ONE, 2013
- Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approachImmunotherapy, 2013
- Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatmentJCI Insight, 2009
- Interleukin-7 improves reconstitution of antiviral CD4 T cellsClinical Immunology, 2005